Our analysis of chemotherapy sensitivity in the two risk subgroups using a prognostic model with macrophage phagocytosis-related genes indicated that low-risk patients showed a greater response to immunotherapy, suggesting that VSIG4 may be a promising target for CRC therapy. Here, VSIG4 is linked to colorectal carcinoma.